Company Analysis: Mitsubishi Tanabe

The publisher explores Mitsubishi Tanabe’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot

Overview - Mitsubishi Tanabe is forecast to maintain a constant sales outlook through 2022, then look to its pipeline to provide growth.
Key themes - [1] Mitsubishi Tanabe’s pipeline revenue will start to make an impact after the launch of vadadustat in 2020, and this will continue with Ingrezza, fasinumab, Uplizna, and ND0612 [2] This impact will be more than enough to offset losses from sales declines in longer-listed products over the bulk of the forecast period [3] Arbitration proceedings with Novartis regarding Gilenya continue to be an overhang that Mitsubishi Tanabe will look to settle [4] Mitsubishi Tanabe Pharma has been consolidated and taken private by its parent company, Mitsubishi Chemical Holdings Corporation.

Model Updates (4 November 2020)

Model Updates (30 October 2019)

ND0612 forecast added, with launch in 2022
Radicut forecast adjusted lower due to already reaching most patients who were waiting for approval in the US.

Model Updates (14 August 2019)

Canalia forecast adjusted lower due to company guidance
Ceredist forecast adjusted higher due to performance against generic competition
Ingrezza forecast adjusted lower due to delayed launch until 2022
Jebik V forecast adjusted lower due to company guidance
Kremezin forecast adjusted higher due to company guidance
Mearubik forecast adjusted lower due to company guidance
Radicut forecast adjusted lower for withdrawal in Europe
Remicade forecast adjusted higher due to company guidance
Fasinumab forecast added.

Company Background

Company Forecast

Company Profile

Clinical Trial Overview

Table of Contents